Novartis Foradil Higher-Dose Phase IV Studies Slated For Completion By 2003
Executive Summary
Novartis will study higher doses of Foradil (formoterol) as a postmarketing commitment associated with FDA's Feb. 16 approval of the asthma therapy.
You may also be interested in...
Schering-Plough Puffs Up Asthma Line With Foradil From Novartis
Schering-Plough is plugging a hole in its asthma product line by in-licensing Novartis' Foradil
Schering-Plough Puffs Up Asthma Line With Foradil From Novartis
Schering-Plough is plugging a hole in its asthma product line by in-licensing Novartis' Foradil
Novartis Foradil Heart Monitoring Phase IV Required With COPD Approval
Novartis will conduct holter heart monitoring in Foradil Aerolizer patients as a Phase IV commitment following the approval of formoterol for chronic obstructive pulmonary disease Sept. 25.